As of 11:10am ET
| +0.07 / +1.07%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 14.75, with a high estimate of 23.00 and a low estimate of 6.50. The median estimate represents a +122.14% increase from the last price of 6.64.
The current consensus among 5 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.